Information Library
Results for: White Papers - Get to market faster
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
An Integrated Approach to Biosimilar Development & Commercialization
September 29, 2011
As the market for biosimilar products continues to grow, many biopharmaceutical companies trying to enter the space are struggling to overcome the unique challenges that developing such products presents. -
Oncology Drug Development and Value-Based Medicine
November 5, 2010
This report demonstrates the need to converge clinical and commercial imperatives earlier within the drug development process to meet a future demand for value-based medical practices. -
Using Real-Time Data to Drive Better Decisions, Faster
September 30, 2010
This white paper examines the advantages afforded by access to real-time data during the course of a clinical trial. -
Navigating Future Challenges in Alzheimer's Disease Trials
September 21, 2010
Quintiles’ own Alzheimer’s experts, Amir Kalali, Roza Hayduk and Lynne Hughes, sum up the insights and discoveries that could lead to the next breakthrough for Alzheimer’s disease. -
A Blueprint for Clinical / Commercial Convergence
August 5, 2010
The development model for bio pharmaceutical companies must shift from two divergent paths to one that combines these two resources with market access strategy, information and capabilities. -
FDA Requirements for Clinical Studies in Pediatric Patients
April 1, 2010
FDA Requirements for Clinical Studies in Pediatric Patients FDA rules around pediatric drug trials have been tightening, to ensure more targeted data on drug efficacy -
Data-Driven Patient Recruitment
March 23, 2010
Under pressure to deliver more evidence faster, drug developers are constantly searching for more patients for clinical trials. -
Regulations for Clinical Studies in Pediatric Patients in the European Union
March 10, 2010
After the United States issued pediatric drug study requirements, the European Union (EU) passed a regulation that created major changes to clinical studies for pediatric -
New FDA Guidance on Antidiabetic Therapies
December 11, 2009
Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program. -
Chasing Influenza
November 30, 2009
The rise in influenza strains like H1N1 — and the demand for new vaccines — signals a new era in vaccines. Learn how flu vaccines have evolved and where they’re headed.
Page 1 of 1 (10 results)
